Johnson & Johnson (NYSE:JNJ) Shares Sold by CNB Bank

CNB Bank reduced its position in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,199 shares of the company’s stock after selling 155 shares during the period. Johnson & Johnson comprises about 1.0% of CNB Bank’s portfolio, making the stock its 23rd biggest holding. CNB Bank’s holdings in Johnson & Johnson were worth $1,912,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in JNJ. Cooke & Bieler LP raised its position in Johnson & Johnson by 5.8% during the fourth quarter. Cooke & Bieler LP now owns 858,687 shares of the company’s stock worth $134,591,000 after acquiring an additional 47,251 shares during the period. J.W. Cole Advisors Inc. raised its position in Johnson & Johnson by 14.7% during the fourth quarter. J.W. Cole Advisors Inc. now owns 62,614 shares of the company’s stock worth $9,814,000 after acquiring an additional 8,038 shares during the period. Castle Wealth Management LLC raised its position in Johnson & Johnson by 9.3% during the fourth quarter. Castle Wealth Management LLC now owns 10,386 shares of the company’s stock worth $1,628,000 after acquiring an additional 888 shares during the period. Kraft Davis & Associates LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $333,000. Finally, ZWJ Investment Counsel Inc. grew its holdings in shares of Johnson & Johnson by 4.8% during the fourth quarter. ZWJ Investment Counsel Inc. now owns 198,306 shares of the company’s stock worth $31,083,000 after buying an additional 9,041 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.2 %

Shares of JNJ stock opened at $146.82 on Friday. The firm has a market cap of $353.80 billion, a PE ratio of 9.15, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The company has a 50-day moving average of $155.47 and a two-hundred day moving average of $155.41.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.68 earnings per share. On average, analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. The ex-dividend date is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 29.68%.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, April 15th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada dropped their price objective on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a report on Wednesday, April 17th. Finally, Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.